Lifestyle First and Lifestyle Always,Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists

The rapid uptake of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, has transformed the management of obesity, diabetes, and cardiometabolic disease, producing substantial weight loss, improved glycemic control, and reduced cardiovascular and renal risk. This article advances a guiding principle for contemporary care: “lifestyle first and lifestyle always, but not lifestyle only.” While GLP-1 RAs have reshaped clinical practice and reinforced recognition of obesity as a biologically mediated disease, pharmacotherapy alone cannot resolve the complex behavioral, physiologic, and social drivers of cardiometabolic risk. Discontinuation of GLP-1 RAs without structured lifestyle support commonly results in weight regain, and medication does not address sarcopenia, physical deconditioning, sleep, stress, psychosocial determinants, or social connection. Lifestyle behaviors, high-quality nutrition, regular physical activity including resistance training, restorative sleep, stress management, social connectedness, and a sense of purpose, constitute the physiological and behavioral foundation for durable health gains. GLP-1 RAs are therefore positioned not as substitutes for lifestyle change, but as catalysts that create metabolic and psychological conditions that are favorable to adopting and sustaining healthy behaviors. Integrated, interprofessional models that combine pharmacologic and lifestyle strategies, supported by policy and systems change, are proposed as the emerging standard for long-term cardiometabolic health.